NasdaqGS - Delayed Quote USD

Biogen Inc. (BIIB)

202.46 +0.47 (+0.23%)
At close: April 25 at 4:00 PM EDT
200.01 -2.45 (-1.21%)
After hours: April 25 at 7:30 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Christopher A. Viehbacher President, CEO & Director 487.94k -- 1961
Mr. Michael R. McDonnell CPA Executive VP & CFO 2.12M -- 1964
Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology 1.46M -- --
Ms. Susan H. Alexander Esq. Executive VP & Chief Legal Officer 2.2M -- 1957
Dr. Ginger Gregory Executive VP & Chief Human Resources Officer 1.59M -- 1968
Ms. Robin C. Kramer Senior VP & Chief Accounting Officer -- -- 1966
Mr. Charles E. Triano Senior VP & Head of Investor Relations -- -- --
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs -- -- --
Mr. Adam Keeney Ph.D. Executive VP & Head of Corporate Development -- -- --
Ms. Alisha A. Alaimo President & Head of North America -- -- --

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000 https://www.biogen.com
Sector: 
Healthcare
Full Time Employees: 
7,570

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 2; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jul 23, 2024 - Jul 29, 2024
Biogen Inc. Earnings Call

Related Tickers

GILD Gilead Sciences, Inc.
65.27
-2.70%
 
AMGN Amgen Inc.
269.38
-1.33%
 
BMY Bristol-Myers Squibb Company
44.70
-8.51%
 
LLY Eli Lilly and Company
724.87
-1.00%
 
NVS Novartis AG
99.06
+0.72%
 
PFE Pfizer Inc.
25.26
-3.84%
 
ABBV AbbVie Inc.
167.29
-0.30%
 
JNJ Johnson & Johnson
146.82
-1.15%
 
MRK Merck & Co., Inc.
130.72
+2.93%
 
AZN AstraZeneca PLC
75.03
+5.38%